middle.news
How Will Prescient’s EMA Orphan Drug Status Propel PTX-100’s Global Trial?
9:29am on Friday 30th of January, 2026 AEDT
•
Healthcare
Read Story
How Will Prescient’s EMA Orphan Drug Status Propel PTX-100’s Global Trial?
9:29am on Friday 30th of January, 2026 AEDT
Key Points
EMA grants Orphan Drug Designation for PTX-100 in CTCL
European approval received to start Phase 2a clinical trial
Global clinical site expansion with 10 sites activated including Italy
Cash reserves at $9.7 million with $4.3 million R&D tax refund received post-quarter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PRESCIENT THERAPEUTICS (ASX:PTX)
OPEN ARTICLE